The Swedish pharmaceutical company Moberg Derma, which focuses on skin diseases, has started recruiting patients for a clinical phase III trial of the K101 product candidate to treat nail fungus (onychomycosis). The company plans to include 470 patients in the study at around 40 clinics in Sweden and Poland. Results from the trial are expected in the second half of 2008.
